Clover Health Investments, Corp. held its fourth quarter and full year 2025 earnings call on February 26, 2026. The conference featured company executives discussing results, with materials available on the investor website. Forward-looking statements were noted as subject to risks detailed in SEC filings.
Clover Health Investments, Corp. (CLOV) hosted its Q4 2025 earnings call on February 26, 2026, at 5:00 PM EST. The call was led by Ryan Schmidt, Investor Relations Analyst, who introduced Co-Founder, CEO and Director Andrew Toy, and Chief Financial Officer Peter Kuipers.
Conference call participants included Jonathan Yong from UBS Investment Bank, Research Division, and John Granville Pinney from Canaccord Genuity Corp., Research Division.
The operator opened the session, noting it was being recorded and providing instructions for participants. Schmidt directed listeners to the press release, supplemental slides, and investor deck on investors.cloverhealth.com. A replay of the webcast would be available in the Investor Relations section.
Schmidt cautioned that forward-looking statements during the call were subject to risks and uncertainties, with factors that could cause actual results to differ outlined in SEC filings, including the Risk Factors section of the most recent Form 10-K. Information on non-GAAP financial measures, including reconciliations to GAAP, was available in the earnings materials on the website.
Andrew Toy began his remarks by thanking Schmidt and welcoming attendees to Clover's fourth quarter earnings discussion.